Table 5.
Follow-Up | ||||
---|---|---|---|---|
General Population | AET | RET | p-Value | |
n = 36 | n = 16 | n = 20 | ||
Follow-up, months | 34 ± 3.6 | 38.2 ± 1 | 31 | <0.001 |
BC recurrency at FU, n (%) | 2 (5.6%) | 1 (6.2%) | 1 (5%) | 0.99 |
Hospitalization for CV issues, n (%) | 1 (2.8%) | 1 (6.2%) | 0 (0%) | <0.001 |
Novel CV medications, n (%) | 2 (5.6%) | 2 (13.4%) | 0 (0%) | <0.001 |
IPAQ | 2160 [600–3990] | 2160 [990.0, 3400.0] | 2212.5 [540.0, 5730.0] | 0.90 |
High level | 15 (41.7%) | 6 (37.5%) | 11 (55%) | 0.39 |
Low level | 9 (25%) | 2 (13.4%) | 7 (35%) | 0.012 |
Moderate level | 11 (30.5%) | 8 (50%) | 1 (5%) | 0.10 |
SAQ-7 | 100.0 [86.1, 100] | 100 [100, 100] | 88.9 [86.1, 100.0] | 0.13 |
SAQ-PL | 100.0 [58.3, 100] | 101 [100, 100] | 75 [58.3, 100] | 0.26 |
SAQ-AF | 100.0 [100, 100] | 100 [100, 100] | 100 [100, 100] | 0.41 |
SAQ-QL | 100.0 [100, 100] | 100 [100, 100] | 100 [100, 100] | 0.41 |
SF-36 | ||||
PF | 75 [65, 80] | 75 [70, 85] | 70 [65, 80] | 0.56 |
SC | 67 [44, 89] | 56 [44, 100] | 67 [56, 89] | 0.64 |
MH | 68 [52, 84] | 72 [52, 84] | 62 [52, 84] | 0.51 |
P | 67 [44, 89] | 67 [44, 100] | 61.5 [44, 89] | 0.97 |
RLP | 50 [25, 100] | 75 [0, 100] | 50 [25, 100] | 0.88 |
RLM | 67 [33, 100] | 67 [33, 100] | 67 [33, 100] | 0.87 |
EV | 50 [35, 70] | 55 [35, 70] | 47.5 [40, 75] | 0.63 |
HP | 55 [35, 80] | 55 [40, 85] | 50 [35, 80] | 0.63 |
List of abbreviations: AET, aerobic exercise training; RET, resistance exercise training; BC, breast cancer; FU, follow-up; CV, cardiovascular; IPAQ, International Physical Activity Questionnaire; SAQ-7, Seattle Angina Questionnaire-7; SAQ-PL; SAQ-AF; SAQ-QL; SF-36, Short Form Health Survey-36; PF, physical function; SC, social function; MH, mental health; P, pain; RLP, role limitation physical; RLM, role limitation mental; EV, vital energy; HP, health perception. Bold values denote statistical significance at the p < 0.05 level.